PharMerica at multi-year high after strong Q3 report

|About: PharMerica Corporation (PMC)|By:, SA News Editor

PharMerica (PMC +25.7%) soars after smashing the estimate of analysts with its Q3 report.

Results were boosted by cost-containment measures and an industry-leading generic dispensing rate of 83.3%.

The company boosted its forecast for full-year EPS to $1.71-$1.76, up from a prior range of $1.55-$1.60 and above the consensus estimate of analysts of $1.60.(PR)